These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445 [TBL] [Abstract][Full Text] [Related]
10. Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes. Luque-Ortega JR; Rivas L Antimicrob Agents Chemother; 2007 Apr; 51(4):1327-32. PubMed ID: 17283192 [TBL] [Abstract][Full Text] [Related]
11. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages. Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367 [TBL] [Abstract][Full Text] [Related]
16. Overexpression of histone H2A modulates drug susceptibility in Leishmania parasites. Singh R; Kumar D; Duncan RC; Nakhasi HL; Salotra P Int J Antimicrob Agents; 2010 Jul; 36(1):50-7. PubMed ID: 20427152 [TBL] [Abstract][Full Text] [Related]
17. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain. Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765 [TBL] [Abstract][Full Text] [Related]
18. Miltefosine-unresponsive Leishmania donovani has a greater ability than miltefosine-responsive L. donovani to resist reactive oxygen species. Das M; Saudagar P; Sundar S; Dubey VK FEBS J; 2013 Oct; 280(19):4807-15. PubMed ID: 23890327 [TBL] [Abstract][Full Text] [Related]
19. Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs. Rastrojo A; García-Hernández R; Vargas P; Camacho E; Corvo L; Imamura H; Dujardin JC; Castanys S; Aguado B; Gamarro F; Requena JM Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):246-264. PubMed ID: 29689531 [TBL] [Abstract][Full Text] [Related]
20. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis. Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]